IPP Bureau
Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant
By IPP Bureau - October 05, 2024
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Emcure signs agreement with Gilead for manufacture and supply of Lenacapavir
By IPP Bureau - October 04, 2024
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Biocon Biologics refinances US$ 1.1 billion debt through USD bonds, new syndicated facility
By IPP Bureau - October 04, 2024
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin
By IPP Bureau - October 04, 2024
This is used to treat central diabetes insipidus and bedwetting
Piramal Pharma releases Sustainability Report FY 2023-24
By IPP Bureau - October 04, 2024
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
Alembic receives USFDA final approval for Alcaftadine Ophthalmic Solution, 0.25% (OTC)
By IPP Bureau - October 04, 2024
Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander
Lilly invests US$ 4.5 billion to create advanced research and manufacturing site
By IPP Bureau - October 04, 2024
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
SK pharmteco invests US$ 260 million to expand global small molecule, peptide production
By IPP Bureau - October 04, 2024
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Indoco Remedies receives final ANDA approval from the USFDA for Cetirizine Hydrochloride Tablets
By IPP Bureau - October 04, 2024
Cetirizine is used for relief of symptoms of hay fever and other allergic conditions
CCI approves acquisition of Bharat Serums and Vaccines by Mankind Pharma
By IPP Bureau - October 03, 2024
The transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines (BSV) by Mankind Pharma
Alembic Pharmaceuticals receives USFDA final approval for Lamotrigine Extended-Release Tablets
By IPP Bureau - October 03, 2024
Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures
Chemify gets grant to design and discover new drug leads for Tuberculosis and Malaria
By IPP Bureau - October 03, 2024
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Clariant to launch eight new high-performing excipients at the CPHI Milan 2024
By IPP Bureau - October 03, 2024
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Sun Pharma and Philogen enter into a exclusive commercialization and supply agreement for Fibromun
By IPP Bureau - October 02, 2024
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Zydus receives EIR for the transdermal manufacturing facility
By IPP Bureau - October 02, 2024
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
